Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer

NCT00900627 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00900627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00900627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2009
Completion date
February 28, 2015
Enrollment
330 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, neoplasms